The latest gathering in Geneva brought together 500+ specialists to discuss non-invasive diagnostic tools and breakthroughs in cardiac amyloidosis care, with a renewed focus on early-detection biomarkers.
Over three days, clinicians and researchers presented new evidence on imaging techniques, biomarker panels, and treatment pathways that could shorten the time to diagnosis for patients with transthyretin and light-chain amyloidosis. Panel discussions emphasized the need for standardized referral protocols between cardiologists and rare-disease centers.
The Alliance will publish a full summary of the congress proceedings in the coming weeks, including recommendations for member associations on how to relay these findings to national health authorities.